These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

88 related articles for article (PubMed ID: 11811127)

  • 1. [Fluvoxamine (fevarin) in psychogenic depression].
    Dubnitskaia EB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(12):48-50. PubMed ID: 11811127
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fluvoxamine (fevarin) in the treatment of depression].
    Sheĭfer MS; Tsybina MI; Davydenko MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):64-7. PubMed ID: 11195542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Therapeutic action and efficiency of fevarin (fluvoxamine) in patients with non-psychotic anxious and apathic-adynamic depressions].
    Neznamov GG; Siuniakov SA; Teleshova ES; Dorofeeva OA; Chumakov DB; Davydova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):19-24. PubMed ID: 11552628
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antidepressant efficacy in relation to item analysis and severity of depression: a placebo-controlled trial of fluvoxamine versus imipramine.
    Kasper S; Möller HJ; Montgomery SA; Zondag E
    Int Clin Psychopharmacol; 1995 Jan; 9 Suppl 4():3-12. PubMed ID: 7622821
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
    Rapaport M; Coccaro E; Sheline Y; Perse T; Holland P; Fabre L; Bradford D
    J Clin Psychopharmacol; 1996 Oct; 16(5):373-8. PubMed ID: 8889909
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Pharmacogenomics J; 2004; 4(4):283-6. PubMed ID: 15148501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients in menopause transition.
    Ushiroyama T; Ikeda A; Ueki M
    J Med; 2004; 35(1-6):151-62. PubMed ID: 18084873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
    Miljković BR; Pokrajac M; Timotijević I; Varagić V
    Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Flupenthixol and fluvoxamine in mild to moderate depression: a comparison in general practice.
    Hamilton BA; Jones PG; Hoda AN; Keane PM; Majid I; Zaidi SI
    Pharmatherapeutica; 1989; 5(5):292-7. PubMed ID: 2501801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and tolerability of Paroxetine 20 mg daily in the treatment of depression and depression associated anxiety.
    Chaudhry HR; Qureshi Z; Tareen IA; Yazdani I
    J Pak Med Assoc; 2002 Nov; 52(11):518-25. PubMed ID: 12585372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of fluvoxamine on depression, anxiety, and other areas of general psychopathology in bulimia nervosa.
    Fichter MM; Leibl C; Krüger R; Rief W
    Pharmacopsychiatry; 1997 May; 30(3):85-92. PubMed ID: 9211569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
    Davidson J; Yaryura-Tobias J; DuPont R; Stallings L; Barbato LM; van der Hoop RG; Li D
    J Clin Psychopharmacol; 2004 Apr; 24(2):118-25. PubMed ID: 15206657
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The status of fluvoxamine among the antidepressive agents].
    Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V
    Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression.
    Ladd CO; Newport DJ; Ragan KA; Loughhead A; Stowe ZN
    Depress Anxiety; 2005; 22(2):94-7. PubMed ID: 16094663
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An open-label trial of nefazodone in high comorbidity panic disorder.
    DeMartinis NA; Schweizer E; Rickels K
    J Clin Psychiatry; 1996 Jun; 57(6):245-8. PubMed ID: 8666561
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual-dual action? Combining venlafaxine and mirtazapine in the treatment of depression.
    Malhi GS; Ng F; Berk M
    Aust N Z J Psychiatry; 2008 Apr; 42(4):346-9. PubMed ID: 18330778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.